<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Consensus guidelines on anti-<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> antibody (aCL) testing have been developed to help minimise laboratory variation in the performance and reporting of aCL assays </plain></SENT>
<SENT sid="1" pm="."><plain>These guidelines include minimum, optimum and optional recommendations for the following aspects of aCL testing and reporting: (1) isotype of aCL tested; (2) specimen type; (3) controls and assay precision; (4) calibrators; (5) patient samples; (6) rheumatoid factors and IgM aCL testing; (7) reporting of results; (8) cut-off values; and (9) interpretative comments </plain></SENT>
<SENT sid="2" pm="."><plain>Abbreviations: aCL, anti-<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> antibodies; APS, anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibody syndrome; ASCIA, Australasian Society of Clinical Immunology and <z:e sem="disease" ids="C0869403,C0700625,C0020517" disease_type="Pathologic Function;Disease or Syndrome" abbrv="">Allergy</z:e>; ASTH, Australasian Society of <z:mp ids='MP_0005048'>Thrombosis</z:mp> and Haemostasis; beta2-GPI=beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I; ELISA, enzyme-linked immunosorbent assay; NCCLS, National Committee for Clinical Laboratory Standards; HSANZ, Haematology Society of Australia and New Zealand; QAP, Quality Assurance Program; RCPA, Royal College of Pathologists of Australasia; %CV, inter-assay inter-run coefficient of variation </plain></SENT>
</text></document>